Navigation Links
GlaxoSmithKline Announces Waiver of a Condition to the Tender Offer for Genelabs Technologies, Inc.
Date:12/3/2008

LONDON and PHILADELPHIA, Dec. 3 /PRNewswire-FirstCall/ -- GlaxoSmithKline (LSE/NYSE: GSK) announced today that it is waiving a condition relating to a pending lawsuit in the previously announced tender offer to purchase all of the outstanding shares of common stock of Genelabs Technologies, Inc. (Nasdaq: GNLB), for $1.30 per share in cash without interest and less any required withholding taxes.

It is a condition to the completion of the tender offer that there not be any pending or threatened claim by or before any governmental entity challenging the making or consummation of the offer or contemplated merger or seeking to enjoin the offer or merger. GSK has waived this condition solely to the extent that it would not be satisfied as a result of the fact that the putative shareholder class action lawsuit, Lanre Rotimi Rollover IRA v. Genelabs Technologies, Inc., et al. is pending in the United States District Court Northern District of California, San Francisco Division. As of December 3, 2008, there was no injunction or order entered pursuant to this lawsuit, which GSK and Genelabs believe is entirely without merit. GSK has not waived any rights with respect to any other lawsuit or with respect to the entry of any injunction or order in this lawsuit.

The tender offer was commenced on November 12, 2008 and is scheduled to expire at 12:00 midnight EST on Wednesday, December 10, 2008, unless extended. The tender offer is being made pursuant to a previously announced Agreement and Plan of Merger dated October 29, 2008 among Genelabs, Gemstone Acquisition Corporation and SmithKline Beecham Corporation, a wholly-owned subsidiary of GSK.

All other terms and conditions of the tender offer remain the same, including th
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. GlaxoSmithKline Commences Tender Offer to Acquire Genelabs Technologies, Inc.
2. GlaxoSmithKline to Acquire Genelabs Technologies to Increase Focus on Novel Small Molecule Therapies for Hepatitis C
3. GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimers Disease Candidate Vaccines
4. GlaxoSmithKline and Cellzome Announce Major Strategic Alliance
5. GlaxoSmithKline Offers New Purchasing Options to Help Employers Overcome Barriers to Pandemic Stockpiling of Relenza(R)
6. GlaxoSmithKline To Post Quarterly US Grants Report
7. GlaxoSmithKline - Q2 Results and Strategy Update - Interview with CEO
8. Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
9. CDC Immunization Advisory Committee Recommends Two New Pediatric Vaccines from GlaxoSmithKline
10. FDA Approves GlaxoSmithKlines AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
11. GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 2013  Rahal Letterman Lanigan Racing (RLL) and StemCyte, ... cell banking and therapeutics, announced today that StemCyte has ... Stairlifts Indy car driven by James Jakes ... IZOD IndyCar 2013 season.   StemCyte, Inc. and ... awareness of umbilical cord blood banking and its educational ...
(Date:5/23/2013)... , May 23, 2013 Virobay, Inc. today ... pain has reached an important milestone, as Virobay has ... - a selective cathepsin S inhibitor.   ... double-blind, randomized, placebo-controlled study designed to evaluate the safety, ... in healthy adults. "The initiation of this ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 The New ... STEM industries, Black Data Processing Associates (BDPA), is hosting ... June 8, 2013. This all-day event will encourage students ... learn the ins and outs from many of the ... p.m. at the New Jersey Institute of Technology, the ...
(Date:5/23/2013)... Tucson, Ariz. (PRWEB) May 23, 2013 ... world’s first and only FDA, Health Canada and CE ... Glasgow Science Centre in Scotland, which boasts more than ... Total Artificial Heart powered by the Freedom® portable ... one of the most advanced exhibitions of its kind. ...
Breaking Biology Technology:StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Black Data Processing Associates (BDPA) New Jersey Hosts 10th Annual Families in Technology Day June 8, 2013 2SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 2SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 3
... May 13 Based on its recent analysis ... Precision Biosciences with the 2009 North American Frost ... Year. The company,s radical Directed Nuclease Editor(TM) (DNE) ... of a cell,s genome with high sequence specificity. ...
... Clinical Pathology (ASCP) has joined the American Civil Liberties ... patents on human genes -- specifically, patents covering the ... and ovarian cancer. The lawsuit was filed against ... Directors of the University of Utah Research Foundation in ...
... /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: MDG), a biotechnology ... vaccines based on proprietary manufacturing technologies and Virus-Like ... expressed a new VLP antigen ("H1 VLP") from ... recent Influenza outbreak in North America and other ...
Cached Biology Technology:Frost & Sullivan Awards Precision Biosciences for Technology Innovation and Molecular Design Process in the Genomics Market 2Frost & Sullivan Awards Precision Biosciences for Technology Innovation and Molecular Design Process in the Genomics Market 3Frost & Sullivan Awards Precision Biosciences for Technology Innovation and Molecular Design Process in the Genomics Market 4ASCP Joins ACLU Lawsuit Opposing Gene Patents 2ASCP Joins ACLU Lawsuit Opposing Gene Patents 3Medicago succesfully expresses VLP antigen for A H1N1 strain 2
(Date:5/23/2013)... The tight wrapping of genomic DNA around nucleosomes ... gene expression. A team of Ludwig-Maximilians-Universitaet (LMU) in ... DNA to be locally displaced from nucleosomes for ... is stored in the cell nucleus, wrapped around ... pairs of four different histone proteins and accommodating ...
(Date:5/23/2013)... cerebral palsy with autologous cord blood. Following a cardiac ... boy had been in a persistent vegetative state ... treatment with the cord blood containing stem cells, the ... learned to speak simple sentences and to move. "Our ... the long-held doubts about the effectiveness of the new ...
(Date:5/23/2013)... Wis. In an age when microbial pathogens are ... tamp down infection, a team of Wisconsin scientists has ... curbing the bacteria that cause staph infections. , Writing ... Society , a group led by University of Wisconsin-Madison ... with the "quorum sensing" behavior of Staphylococcus aureus ...
Breaking Biology News(10 mins):Biochemistry: Unspooling DNA from nucleosomal disks 2First successful treatment of pediatric cerebral palsy with autologous cord blood 2University of Wisconsin chemists find new compounds to curb staph infection 2
... COLLEGE STATION A joke among two Texas ... found Viagra can aid fetal development in female sheep. ... can serve as an excellent animal model for studying ... Viagra (sildenafil citrate), which is used to treat male ...
... HEALTH CARE - Maximizing mammography . . . ... a technology being developed by researchers at Oak Ridge National ... allow doctors to quickly identify trends specific to an individual ... of known cancerous and pre-cancerous conditions. "Our goal is to ...
... LA JOLLA, CA February 3, 2010 For Immediate ... Institute has identified two compounds that act on novel binding ... (HIV), the virus that causes AIDS. The discovery lays the ... drugs to enhance existing therapies, treat drug-resistant strains of the ...
Cached Biology News:Study shows male erectile dysfunction drug enhances fetal growth in female sheep 2Story tips from the US Department of Energy’s Oak Ridge National Laboratory February 2010 2Story tips from the US Department of Energy’s Oak Ridge National Laboratory February 2010 3Scripps Research scientists find two compounds that lay the foundation for a new class of AIDS drug 2Scripps Research scientists find two compounds that lay the foundation for a new class of AIDS drug 3Scripps Research scientists find two compounds that lay the foundation for a new class of AIDS drug 4Scripps Research scientists find two compounds that lay the foundation for a new class of AIDS drug 5
... Express Cloning Checker Kits provide two ... after transformation without time-consuming plasmid preparation. By ... I, all you need to do is ... bacteria directly from the transformation plates into ...
... perfusion system. For real-time or pre-programmed ... electrochemistry, or general liquid-handling research applications. ... accuracy Run experiments automatically - ... and flexibility Turnkey perfusion system ...
... GenBank Accession Number : NM_006225 ... fusion protein corresponding to full length rat ... 7.4, 0.15M NaCl, 0.05% sodium azide before ... Assurance: routinely evaluated by immunoblot on RIPA ...
...
Biology Products: